STAMFORD, Conn., May 30, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with ...
STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a Stamford, ...
--SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that three abstracts from the pivotal Phase 2 b ReNeu trial ...
SpringWorks Therapeutics, part of Merck KGaA, has received conditional marketing authorization from the European Commission for its drug EZMEKLY® (mirdametinib), marking the first approved treatment ...
SpringWorks Therapeutics, a Merck company, announced that the European Commission has granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of symptomatic, ...
STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from ...
Hosted on MSN
SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout
Shares of SpringWorks Therapeutics Inc. ended over 9% higher on Thursday following a report that the company is inching closer to getting acquired by an established giant, triggering a jump in ...
STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results